ANDA 89029, held by Hikma Pharmaceuticals. Procainamide Hydrochloride.
As of Nov 21, 2026, ANDA 89029 (Procainamide Hydrochloride), held by Hikma Pharmaceuticals, was first approved by FDA on Apr 17, 1986, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 17, 1986 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Procainamide Hydrochloride100MG/ML · injectable;injection | Procainamide Hydrochloride | Discontinued |
| Apr 3, 2000 | Supplement 9Manufacturing | Approved | None posted |
| Jun 12, 1998 | Supplement 8Labeling | Approved | None posted |
| Dec 9, 1991 | Supplement 6Labeling | Approved | None posted |
| Nov 7, 1988 | Supplement 5Labeling | Approved | None posted |
| Mar 4, 1988 | Supplement 4Manufacturing | Approved | None posted |
| Nov 3, 1986 | Supplement 2Manufacturing | Approved | None posted |
| Sep 5, 1986 | Supplement 1Manufacturing | Approved | None posted |
| Apr 17, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters